Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 19

1.

Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.

Uzui H, Morishita T, Nakano A, Amaya N, Fukuoka Y, Ishida K, Arakawa K, Lee JD, Tada H.

J Cardiovasc Pharmacol Ther. 2014 May;19(3):304-9. doi: 10.1177/1074248413511692. Epub 2013 Nov 28.

PMID:
24288395
2.

Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients.

Doi M, Miyoshi T, Hirohata S, Kamikawa S, Usui S, Kaji Y, Sakane K, Ogawa H, Ninomiya Y, Kusachi S.

Am J Med Sci. 2010 May;339(5):433-9. doi: 10.1097/MAJ.0b013e3181d658c4.

PMID:
20234301
3.

Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial.

Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y.

PLoS One. 2015 May 4;10(5):e0125519. doi: 10.1371/journal.pone.0125519. eCollection 2015.

4.

Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.

Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Shimada K, Ito S, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Kimura G, Umemura S, Ura N, Hayashi K, Odawara M, Tanahashi N, Ishimitsu T, Kashihara N, Morita S, Teramukai S; COLM Investigators.

J Hypertens. 2014 Oct;32(10):2054-63; discussiom 2063. doi: 10.1097/HJH.0000000000000281.

5.

Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis.

Rakugi H, Ogihara T, Saruta T, Kawai T, Saito I, Teramukai S, Shimada K, Katayama S, Higaki J, Odawara M, Tanahashi N, Kimura G; COLM Investigators.

J Hypertens. 2015 Oct;33(10):2165-72. doi: 10.1097/HJH.0000000000000668.

6.
7.

Changes in left ventricular relaxation after azelnidipine treatment in hypertensive patients with diabetes: subanalysis of a prospective single-arm multicentre study.

Iwakura K, Ito H, Ishii K, Date M, Nakamura F, Nagano T, Takiuchi S; Clinical impact of Azelnidipine on Left VentricuLar diastolic function and OutComes in patients with hypertension (CALVLOC) trial investigators.

BMJ Open. 2014 Sep 30;4(9):e006136. doi: 10.1136/bmjopen-2014-006136.

8.

Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.

Kato H, Shiraishi T, Ueda S, Kubo E, Shima T, Nagura M, Yano H, Izumikawa Y, Shimada M, Tomioka S, Nosaka H, Kojima K, Tanemoto M, Uchida S.

Clin Exp Nephrol. 2015 Jun;19(3):465-73. doi: 10.1007/s10157-014-1017-7. Epub 2014 Aug 19.

9.

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K.

Am J Med Sci. 2007 Jun;333(6):321-6.

PMID:
17570983
10.

[Effect of olmesartan medoxomil on arterial stiffness in patients with essential hypertension].

Mediavilla García JD, Fernández-Torres C, Jaén Aguila F, Jiménez-Alonso J.

Med Clin (Barc). 2007 May 19;128(19):726-9. Spanish.

PMID:
17565879
11.

Why COLM and ACCOMPLISH study results differ.

Cífková R.

J Hypertens. 2014 Oct;32(10):1967-9. doi: 10.1097/HJH.0000000000000332. No abstract available.

PMID:
25186528
12.

Effects of Add-on Therapy Consisting of a Selective Mineralocorticoid Receptor Blocker on Arterial Stiffness in Patients with Uncontrolled Hypertension.

Shibata T, Tsutsumi J, Hasegawa J, Sato N, Murashima E, Mori C, Hongo K, Yoshimura M.

Intern Med. 2015;54(13):1583-9. doi: 10.2169/internalmedicine.54.3427. Epub 2015 Jul 1.

13.

[Up-to-Date Aspects of Antihypertensive Therapy from the Viewpoint of Cardio- and Nephroprotective Action: Olmesartan].

Evdokimova AG, Ryzhova YV.

Antibiot Khimioter. 2015;60(5-6):34-40. Review. Russian.

PMID:
26852494
14.

Effects of olmesartan on endothelial progenitor cell mobilization and function in carotid atherosclerosis.

Gong X, Shao L, Fu YM, Zou Y.

Med Sci Monit. 2015 Apr 26;21:1189-93. doi: 10.12659/MSM.892996.

15.
16.

Effect of olmesartan on leukocyte recruitment in choroid-sclera complex in hypercholesterolemia model.

Torres RJ, de Noronha L, Casella AM, Grobe SF, Martins Ide C, Torres Rdo R, Luchini A, Sturzeneker MC, Torres CL, Precoma DB.

J Ocul Pharmacol Ther. 2013 Oct;29(8):709-14. doi: 10.1089/jop.2012.0142. Epub 2013 May 17.

PMID:
23683100
17.

Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study).

Tawaramoto K, Kaneto H, Hashiramoto M, Kawasaki F, Tatsumi F, Shimoda M, Kamei S, Matsuki M, Mune T, Kaku K.

Diabetol Metab Syndr. 2015 Sep 17;7:80. doi: 10.1186/s13098-015-0073-9. eCollection 2015.

18.

Serum Osteoprotegerin Is Associated With Calcified Carotid Plaque: A Strobe-Compliant Observational Study.

Kwon A, Choi YS, Choi YW, Chung WB, Park CS, Chung WS, Lee MY, Youn HJ.

Medicine (Baltimore). 2016 Apr;95(15):e3381. doi: 10.1097/MD.0000000000003381.

19.

[Arterial bed stiffness in patients with different cardiovascular risk factors].

Nosov AE, Baidina AS, Ivashova YA, Vlasova EM, Alekseev VB.

Ter Arkh. 2016;88(4):20-23. Russian.

PMID:
27070158
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk